Gilead Sciences (Nasdaq: GILD) has sold off a drug once predicted to be a significant player in the myelofibrosis market.
The US biotech giant has sold momelotinib to Canadian company Sierra Oncology (Nasdaq: SRRA) in a deal that includes an upfront fee of $3 million and potential milestone payments that could reach up to $195 million.
Gilead acquired the asset in late 2012 in its $510 million deal to buy YM Biosciences and took it into Phase III trials, but these delivered mixed results.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze